Published online before print January 26, 2004, doi: 10.1161/01.HYP.0000116222.57000.85
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:649.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
Angiotensin II Stimulates Calcium and Nitric Oxide Release From Macula Densa Cells Through AT1 Receptors
From the Department of Medical Cell Biology, Uppsala University, Sweden.
Correspondence to Prof A. Erik G. Persson, Department of Medical Cell Biology, Uppsala University, BMC Box 571, S-75123 Uppsala, Sweden. E-mail erik.persson{at}medcellbiol.uu.se
A fluorescent nitric oxide (NO) indicator, 4,5-diaminofluorescein diacetate, and the calcium indicator, indo-1, with 488 nm and 364 nm UV confocal laser scanning microscopy were used to detect NO and calcium concentration in rabbit macula densa (MD) cells challenged by angiotensin II (Ang II). Glomeruli with attached thick ascending limbs with the MD plaque were isolated and perfused. Ang II concentration from 10-9 to 10-5 progressively increased MD cell calcium and NO to peak values at 10-6 and 10-7, respectively. Ang II (10-6 M) caused the cytosolic calcium concentration ([Ca2+]i) to increase by 125.8±16.3 nM (n=17) from the bath and by 52.3±11.5 nM (n=18) from the lumen. AT1 antagonist CV-11974 (10-6 M) blocked the Ang II-induced calcium responses from bath and lumen, but AT2 antagonist PD-123319 (10-6 M) did not. AT2 agonist CGP-42112A (10-6 M) did not affect [Ca2+]i in MD cells from either side. Ang II (10-6 M) increased the NO production by 16%±3.4% (n=26) from the bath and by 18%±3.1% (n=24) from the lumen. CV-11974 (10-6 M) blocked the NO responses from both sides, but PD-123319 (10-6 M) did not on either side. CGP-42112A (10-6 M) had no effect on NO in MD cells. In calcium-free experiments there was no difference from the result in normal calcium solutions. In conclusion, we found that Ang II increased [Ca2+]i and stimulated NO production in MD cells from the basolateral and luminal sides through AT1 receptors.
Key Words: angiotensin • calcium • nitric oxide • juxtaglomerular apparatus
This article has been cited by other articles:
 |
|
 |
|
  A. Patzak, A. Steege, E. Y. Lai, J. O. Brinkmann, E. Kupsch, N. Spielmann, A. Gericke, A. Skalweit, J. Stegbauer, P. B. Persson, et al. Angiotensin II response in afferent arterioles of mice lacking either the endothelial or neuronal isoform of nitric oxide synthase Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R429 - R437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Stegbauer, Y. Kuczka, O. Vonend, I. Quack, L. Sellin, A. Patzak, A. Steege, K. Langnaese, and L. C. Rump Endothelial nitric oxide synthase is predominantly involved in angiotensin II modulation of renal vascular resistance and norepinephrine release Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R421 - R428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Wilcox Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R913 - R935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Herrera and J. L. Garvin Recent Advances in the Regulation of Nitric Oxide in the Kidney Hypertension, June 1, 2005; 45(6): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Katovich, J. L. Grobe, M. Huentelman, and M. K. Raizada Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension Exp Physiol, May 1, 2005; 90(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|